Purpose Only 53% and 63% of studies and clinical trials results presented at congresses are published. Companysponsored trial results are being posted on publicly accessible Web sites. We analyzed the public availability (publication or posting on a Web site) rate, time to publication, and factors predicting public availability of results of studies sponsored by a pharmaceutical company. Methods This was a retrospective cohort study analyzing all studies conducted by GlaxoSmithKline in Spain between 2001 and 2006. Initiation and completion were defined as first participant/first visit and last participant/last visit (or their equivalents). Papers published up to 31 March 2009 were considered. Logistic regression models were used to identify factors predicting public availability of results. Results The cohort comprised 143 studies (94 clinical trials; of these, 87 were included in international products clinical development plans). Public availability rate was 80% (114/ 143) for all studies and 78% (73/94) for clinical trials; publication rates were 68% and 61%, respectively. The median time to publication for all studies and trials was 27.3 and 28.4 months, respectively. Study associated to a cancelled project was the only significant factor associated with lower publication rate for all studies [odds ratio (OR) 0.069; 95% confidence interval (CI) 0.02-024; p<0.001) and trials (OR 0.075; 95% CI 0.016-0.343; p=0.001) and a lower public availability rate (OR 0.052; 95% CI 0.007-0.382; p=0.004) for trial results. Therapy area, sample size, positive trial results, duration of experimental phase, and being a clinical trial did not predict publication or public availability. Conclusions Eighty percent of studies included in this analysis are publicly available. Web site posting increases public availability rate of clinical trial results from 61% to 78%. Cancellation of projects is the single factor negatively influencing publication and public availability rates.
Introduction
Publication bias regarding clinical trials is well recognized [1] and bears important implications. One is that researchers have no access to all data regarding the intervention of interest. The conclusions of their analyses are therefore bound to be biased but may nevertheless still influence treatment guidelines and decisions. As has been shown, positive studies are more likely to be published than are negative or inconclusive ones [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] , and reviews tend to overestimate the effects of the intervention. Publication of results could be influenced by investigators, sponsors, journal editors, and regulations [14] . Many papers have addressed the publication rate and time to publication of studies and factors influencing them. Most are based on abstracts presented at scientific congresses [6, 7, 12, [15] [16] [17] [18] 24] and studies approved by Research Ethics Committees (REC) or Institutional Review Boards (in the USA) [2-4, 8, 13, 19-22] , studies funded by public agencies [5] , or clinical trials submitted to regulatory agencies [10, 11, 23] . To our knowledge, none of them, however, has used internal data from a pharmaceutical company.
Indeed, controversy persists about how the industry, compared with other sponsors, can affect the publication rate of study results. Some authors have found that industrysponsored studies tend to be less likely to be published than those funded or sponsored by noncommercial organizations [2, 3, 22] . This, however, has not been confirmed by others [15, 20, 24] . Several other factors seem to influence this, with the type of studies under review (e.g., phase 1 and 2 trials are less likely to be published [2, 13, 25] ) being a critical one. Finally, it is worth mentioning a recent report comprising phase 2-4 trials registered at Clinicaltrials.gov showed that industry-sponsored trials (44%) were less likely to be published than were non-industry-/non-governmentsponsored ones (56%), but there was no difference when compared with government-sponsored trials (40%) [26] Following a public debate on the publication of trial results, GlaxoSmithKline (GSK) launched in September 2004 a publicly available, Internet-based clinical trial register (CSR; www.gsk-clinicalstudyregister.com/) to provide results from all GSK-sponsored clinical trials of marketed medicines and vaccines completed since the formation of GSK in 2001 [27] . The aim was to assist physicians in their clinical practice and research, an initiative taken also by other companies and their US trade association. The GSK register contains >3,000 summaries of published and unpublished trials conducted on 52 marketed products.
The objective of this study was to describe the public availability rate and time to publication of studies managed by GSK in Spain, as well as to identify factors that could predict such public availability. The journal impact factor of papers was also determined.
Methods

Studies
This is a retrospective cohort study based on all scientific studies managed by GSK's medical department in Spain. All studies initiated (i.e., first visit of the first participant or its equivalent, e.g., first in vitro test performed; first clinical history reviewed) in 2001 or later and completed (i.e., last visit from the last participant or its equivalent) up to 31 December 2006 were included. Studies managed by international contract research organizations and all follow-up (extension) safety trials were excluded.
Data collection and definitions
A specific database was designed to contain all data gathered from the review of GSK files. Data were collected after a training session on abstraction of study characteristics; four authors (JL, MGL, RDR, RO) reviewed data for consistency before entering it to the database. Discrepancies were resolved by consensus of all authors. Time to publication was defined as the period between study completion (last visit of last participant or its equivalent) and time when the first paper on the study's primary endpoint, was published. Reasons for not publishing were captured. Project is defined as the group of studies comprising the product development plan for a given indication. Cancelled projects (i.e., those prematurely terminated) and the reason for such decisions were also recorded.
Trial results were classified as positive if the protocoldefined hypothesis (primary endpoint) was confirmed (i.e., statistically significant difference in favor of the experimental arm), or negative if the hypothesis did not reach statistical significance, (i.e., not significant or significant in favor of the control arm). For noninferiority trials, results meeting the protocol definition [below the prespecified significance level or a confidence interval (CI) excluding the prespecified difference] were considered positive. When no statistical test was performed, results were considered as positive if classified by investigators as important or striking, and as negative if classified as of moderate or little importance or not striking [28] . Publication was defined only as an original article in a peer-reviewed journal, issued up to 31 March 2009 (cutoff date). For time to publication, only the month and year of publication were considered; an online article was included only if no paper publication was available. Journals impact factors were obtained through the ISI Web of Science (http://admin-apps.isiknowledge.com/ JCR/JCR) for the year of each publication between 1 and 15 April 2009.
Data management and statistical analyses
Quality control was conducted to ensure 100% accuracy and completeness for primary outcomes and main explanatory variables, certifying <1% error in secondary data. Standard descriptive statistics were used for discrete and continuous data. A multivariate logistic regression model was performed to identify factors predicting publication. Two additional models with publication and public availability as outcomes were used only for clinical trials. Factors considered were therapy area, study being associated with a cancelled project, clinical trial, sample size, positive trial result (only for clinical trials models), and duration of experimental phase. Odds ratio (OR) and their 95% CI were calculated. Two multivariate linear regression models were used to identify potential factors explaining time to publication for studies and for clinical trials, respectively. Candidate factors were the same as the above, plus the inclusion of impact factor, which was Lntransformed. Nonstandardized B coefficients were obtained. Only studies with data in all predicting factors were included in the multivariate models. All candidate factors were maintained in the final models; no stepwise procedures were used for selection. Factors were considered significant if P value<0.05. SPSS statistical software version 15.0 was used.
Results
Studies
Only three studies (two follow-up safety trials and one trial not managed by GSK Spain but by an international contract research organization -the latter was eventually published in an international peer-reviewed journal) were excluded from the analysis. The total sample included 143 studies, two thirds (n=94) being clinical trials. Tables 1 and 2 show the distribution by type of study and therapy area. All study protocols comprising human data were approved by the relevant REC; clinical trials protocols were also approved by the Spanish Medicines Agency, and the relevant competent authorities of the participating countries where appropriate. Six studies (four clinical trials and two prospective, drug-related, longitudinal observational studies) were terminated early due to safety (n =3) or recruitment (n = 3). issues Twenty projects, accounting for 22 clinical trials (Table 3) , were prematurely cancelled, most frequently due to lack of efficacy (16/20; 80%) and usually in phase 2 (15/20, 75%). An additional project was cancelled for lack of efficacy on an animal model and after conducting an epidemiological longitudinal prospective study.
Most trials (87/94, 93%) were part of the clinical development plans of investigational medicines and vaccines. Median (range) sample size of clinical trials included in the analysis was 452 (12-5,052) participants. By clinical development phase, these numbers were: 13 (12-56), 290 (13-1,415), 569 (127-5,052), and 458 (120-1,395) for phases 1, 2, 3, and 4, respectively. Tables 1 and 2 , 68% (97/143) of all studies were published in peerreviewed journals, and one was in press, whereas four (3%) had already been submitted by the time of study cutoff date. Moreover, there were 17 (Tables 1 and 2 ) not yet published but posted on CSR. Total public availability (published or posted on GSK CSR) thus reached 80% (114/143). Three out of the six studies prematurely terminated were published (two due to safety reasons, and one prospective, longitudinal, observational, drug-related study due to slow recruitment). GSK was acknowledged as the study sponsor, and/or one or more GSK employees were included among study authors in all published manuscripts. b. Clinical trials (n=94): Sixty-one percent (57/94) of trial results were published (Table 1 ). In addition, two manuscripts had been submitted for publication. Results of 43% (16/37) of the nonpublished trials were posted on CSR, thus reaching 78% (73/94) of public availability rate (Table 1) . Reasons for no publication and publication and publicly available rates stratified by positive or negative results are presented in Table 4 . Results were publicly available for 87% (55/63) positive versus 58% (18/31) negative trials ( Table 4) . Results of trials 
Impact factor
The results of 97 studies were published in 56 different peerreviewed journals (89 papers in 51 international journals). All journals except two are indexed in PubMed and 91% (51/56) by ISI Web of Science. The median impact factors of all published studies and clinical trials were 3.6 and 3.9, respectively; negative trials had higher median impact factor (4.5) than positive ones (3.8) (Tables 2 and 4 ).
Predictors for public availability and time to publication
One hundred and nineteen studies were included in the regressions models, i.e., the entire study sample (n=143) except microbiology (n=20), systematic review (n=1), mathematical model (n=1), and pharmacoeconomic (n=2) Among the six factors selected as candidate predictors in the multivariate logistic regression models, study associated to a cancelled project was the only significant one predicting a lower publication rate for all studies (OR 0.069; 95% CI 0.02-024; p<0.001) and trials (OR 0.075; 95% CI 0.016-0.343; p=0.001), and a lower public availability rate (OR 0.052; 95% CI 0.007-0.382; p=0.004) for trial results. From the linear models, impact factor was the only significant contributor reducing the time to publication: papers submitted to journals with higher impact factors resulted in an earlier publication when total sample (B −5.7; p=0.010) or only clinical trials (B −6.9; p=0.007) are considered. Results of multivariate logistic and linear regression models are shown in Tables 5 and 6 .
Discussion
Despite selective publication being frequently investigated [2-4, 6-8, 10-13, 15-22] , this study is the first analysis produced by a pharmaceutical company. Additionally, and as a novelty, it reports not only publication rate, but also availability of nonpublished study results posted on a Web site (GSK CSR) as a source of reliable information. A recent Cochrane review [9] reported that after 9 years, 53% of congress abstracts are published (with a median lag time of 17.9 months), with this figure increasing to 63% for clinical trials. Our series shows a publication rate of 68% for all studies, with a median lag time of 27.3 months; the corresponding figures being 61% and 28.4 months for clinical trials. Thus, GSK-sponsored studies in Spain have similar publication rates but with a shorter time to publication than those included in the Cochrane report (9 vs 5.5 years) [9] . When nonpublished trial results posted on CSR are added, the public availability rate reaches 78%, (80% when considering the total sample). To put these results into context, only 80% of the Cochrane protocols were published as full reviews after more than 8 years of completion, with a median time to publication of 2.4 years [29] , despite being the most reported systematic reviews [30] . When comparing publication lag time between different studies, a critical element is the time point considered as start for each study. We believe that last participant/last visit date is the best milestone for clinical trials or its equivalent for other types of studies, given its objectivity. Thus, other factors that may influence publication lag time (e.g., database freeze delay) are avoided. Unfortunately, this time point is seldom considered by others, as it is not usually available. The few studies performed using this milestone indicate a median time of 2.4 years to publication for 36 National Institutes of Health-funded human immunodeficiency virus trials [5] , or 23 months from data set finalization to full report publications [31] . These lag times are comparable with the 28.4 months for our 57 published trials. Of note is the fact that most authors when assessing publication rates used different start time points, sometimes not taking into consideration many months or years after study completion; thus, times such as 3-5 years after abstract presentation at congresses [6, 7, 9, 12, 15, 16, 18] or 5-8.5 years after Food and Drug Administration drug approval [10, 11] are common.
Although the pharmaceutical industry has been reportedly involved in selective publication [10, 11, 23] , this is not an industry-specific issue. Thus, Chan [32] recently stated that "accumulating empiric evidence has shown that selective reporting of results is a systemic problem afflicting all types of trials, including those with no commercial input". It is well documented that positive trials are more likely [1-10, 12, 28, 33] and published earlier [4, 5, 7] than are negative ones. Hopewell et al. [33] reported that positive trials are published in 4-5 years, whereas negative or null results take 6-8 years. In our series, positive trials had higher publication (71%) and public availability (87%) rates; negative trials were, on the other hand, less frequently published (39%) and publicly available (58%); for nonpublished studies, the proportion of positive/negative results was 49%/51%. This apparent positive publication bias is, however, rejected by the logistic regression model showing that the factor "study associated to a cancelled project" but not "positive trial result" was the only significant predictor for publication and public availability of a trial result. Hence, positive studies influencing the decision of publication become a confounding factor. Additionally, positive trials were not published significantly earlier.
Although controversial, it is widely accepted that impact factor reflects to some extent the quality and scientific interest of the publication. Median and mean impact factors in our series were 3.9 and 7.5, respectively. Median impact factor ranged from 1.96 to 4.14 [12, 16, 17] and a mean of around 3 [18] in the few studies reporting this variable. In two studies, 24% and 37% of publications were in journals with an impact factor >4 [17] or >5 [13] , respectively. As a comparison, 37% and 20% of the studies assessed in this study were published in journals with an impact factor >4 and >5, respectively. On the other hand, we could speculate that the association of higher impact factor with reduced time to publication may result from higher interest -and hence quicker submission of the paper -on the part of the authors and/or more agile review process by the more important journals.
In this analysis, data from 17 unpublished studies posted on CSR were added to publications. These summary results, as those on other Web sites, lack the context and interpretation that published papers provide [34] and therefore should be a complement to publication rather [35] . This is also a request included in the Declaration of Helsinki that states that positive, negative, or inconclusive trial results "should be published or otherwise made publicly available" [36] . Accordingly, GSK has recently committed to seek publication of results of all clinical trials, observational studies, and meta-analyses, including those on prematurely terminated compounds; furthermore, when study results are not published, the CSR summaries will provide context and interpretation of the same [37] .
Strengths and limitations
The availability of source documents for all published and unpublished studies is a plus for this internal analysis. Most reviews addressing publication fate of studies have been performed by external researchers not involved in them, usually without access to protocols and full reports. This uncommon circumstance [23] enabled all conducted studies to be accounted for, from their start until their final fate, with virtually no missing data. In particular, the availability of the study completion date, critical for calculating time lag to publication, is missing in most reviews [10, 21] . This milestone coincides for almost all studies with the Food and Drug Administration requirement as the time point to count the 12-month period to disclose clinical trial results [14] . On the other hand, it could be argued that as the authors participated in study management and/or publication, this might compromise objectivity. Although this bias cannot be completely ruled out, it is tempered by the nature of the information collected, the quality control measures, and the fact that most (93%) trials were part of international development projects, and therefore most decisions were made by others. The external validity of this analysis could be questioned considering the limited number of studies and the even lower number of clinical trials, although greater than those followed until publication reported by others [4, 5, 13, 19, 21, 23] . Another question is how well this trial sample actually represents the worldwide clinical development of new compounds. Data from the Clinicaltrials.gov database [38] show that in industry-sponsored phase 2-4 trials, the activity in Spain ranks parallel to that in the UK and Italy. Spain has participated in approximately 25% of all GSKsponsored international phase 2-4 drug trials during the study period. Despite the limitations of the analysis presented here, results could nevertheless be considered as a likely representation of the publication and public availability rates of GSK worldwide. Conversely, no data is provided for other pharmaceutical companies in Spain and, therefore, there is no justification for extrapolating these results to other organizations.
The definitions used in this study of positive and negative trial results differ from those used by other researchers. In our analysis, the definition of positive result corresponds to that stated in the protocol for each study, as was done by only a few other authors [8, 9] , instead of meeting some specific criteria defined a posteriori to be applied to studies [2-7, 10-12, 28] . By respecting the criteria set by the authors of each protocol, we rated as positive not only investigator judgements but also those accepted by the RECs and regulatory agencies when approving the clinical trial protocols.
The time lag to publication analysis was applied to a completed set of studies (those with last participant/last visit date <1 Jan 2007). No additional censored data from studies ending beyond this date were considered and, therefore, Cox regression models simultaneously considering public availability and time lag to this endpoint were not employed; it should be noted that this model does not allow invariant calculation of publication and public availability rates. Although Cox regression analysis is used when assessing publication rate because of the nature of the data sets considered, we believe, as have others before [26] , that our approach for a complete data set over a defined time period is more informative.
Conclusion
Eighty percent of studies managed by GSK in Spain are publicly available. When clinical trials are considered, this figure is 78%, comprising a 61% journal publication rate plus an additional 17% of nonpublished trial results posted on CSR -hence substantially increasing public availability rate. As 93% of these clinical trials were multinational, it seems this study could be regarded as reasonably representative of what GSK activity is worldwide. Cancellation of projects is the single factor influencing a lower publication and public availability rate. There is, however, room for improvement for attaining complete public availability of study results conducted by pharmaceutical companies.
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